CR20210513A - Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
CR20210513A
CR20210513A CR20210513A CR20210513A CR20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A
Authority
CR
Costa Rica
Prior art keywords
pyrazino
hexahydro
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
CR20210513A
Other languages
English (en)
Inventor
Hong Shen
Lue Dai
Yongfu Liu
Fabian Dey
Buyu Kou
Zhiwei Zhang
Wei Zhu
Zhisen Zhang
Yafei Liu
Linuo Zhu
Haixia Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210513A publication Critical patent/CR20210513A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La presente invención se refiere a compuestos de fórmula (I), A ( ) n (I), en donde R1 a R3 , n y A son como se describen en la presente, y su sal aceptable desde el punto de vista farmacéutico de estos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CR20210513A 2019-04-09 2020-04-07 Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria CR20210513A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CR20210513A true CR20210513A (es) 2021-11-02

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210513A CR20210513A (es) 2019-04-09 2020-04-07 Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Country Status (18)

Country Link
US (1) US20220340597A1 (es)
EP (1) EP3953356B1 (es)
JP (1) JP2022527588A (es)
KR (1) KR20210149163A (es)
CN (1) CN113710672A (es)
AU (1) AU2020272467A1 (es)
BR (1) BR112021020297A2 (es)
CA (1) CA3135129A1 (es)
CL (1) CL2021002621A1 (es)
CO (1) CO2021013166A2 (es)
CR (1) CR20210513A (es)
IL (1) IL286870A (es)
MA (1) MA55594A (es)
MX (1) MX2021012223A (es)
PE (1) PE20212178A1 (es)
SG (1) SG11202110401WA (es)
TW (1) TW202104230A (es)
WO (1) WO2020207991A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652A (zh) * 2019-10-31 2022-06-07 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
EP4058452A1 (en) * 2019-11-12 2022-09-21 F. Hoffmann-La Roche AG Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
EP4182032A1 (en) * 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348935B (es) * 2011-01-12 2017-07-03 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
HUE037689T2 (hu) 2012-09-14 2018-09-28 Hoffmann La Roche Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
KR20180094939A (ko) * 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
WO2020064792A1 (en) * 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease

Also Published As

Publication number Publication date
CO2021013166A2 (es) 2021-12-10
MA55594A (fr) 2022-02-16
JP2022527588A (ja) 2022-06-02
CL2021002621A1 (es) 2022-05-13
KR20210149163A (ko) 2021-12-08
TW202104230A (zh) 2021-02-01
EP3953356C0 (en) 2023-07-26
BR112021020297A2 (pt) 2021-12-14
MX2021012223A (es) 2021-11-03
EP3953356B1 (en) 2023-07-26
SG11202110401WA (en) 2021-10-28
CA3135129A1 (en) 2020-10-15
US20220340597A1 (en) 2022-10-27
WO2020207991A1 (en) 2020-10-15
CN113710672A (zh) 2021-11-26
EP3953356A1 (en) 2022-02-16
PE20212178A1 (es) 2021-11-09
AU2020272467A1 (en) 2021-10-14
IL286870A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021012105A (es) Compuestos de pirrol.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2021007247A (es) Derivados de rapamicina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CR20210014A (es) Derivados de pirrolo [1,2-b] piridazina
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.